Scholars argue that FDA should use larger health data sets in its approval process for high-risk drugs.
A proposed requirement to display drug list prices in advertisements draws controversy.
Federal health agencies should work together to address public health problems.
Scholars caution against using the Right to Try Act to skirt regulation for regenerative therapies.
U.S. regulators should model the medical device classification process on recent tax reform.
Scholar argues that agencies should collect evidence on surgical procedures to help implement best practices.
Despite ethical concerns, scholar argues that gene editing of human embryos should not be banned.
Scholar argues that FDA should reform its regulation of algorithm-based medicine.
In keynote address, Gary Marchant discusses the transnational implications of genetic engineering.
Policymakers should consider the impact of their decisions on not just wealth, but also human life.
FDA should encourage states to be the primary regulators of stem cell procedures.
Regulatory capture, neither inevitable nor a death trap for agencies, must be reduced to advance public policy goals.